Acute leukemias in children with Down syndrome
Molecular Genetics and Metabolism, ISSN: 1096-7192, Vol: 107, Issue: 1, Page: 25-30
2012
- 39Citations
- 128Captures
- 8Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations39
- Citation Indexes38
- 38
- CrossRef37
- Policy Citations1
- Policy Citation1
- Captures128
- Readers128
- 128
- Mentions8
- References8
- Wikipedia8
Review Description
Children with Down syndrome (DS) often present with hematopoietic abnormalities, and are at increased risk of developing leukemia. Specifically, 3–10% of newborns with DS are diagnosed with transient myeloproliferative disease, and children with DS are 500 times more likely to develop acute megakaryoblastic leukemia (AMKL) and 20 times more likely to develop acute lymphoblastic leukemia (ALL) than typical children. This review examines the characteristics of these leukemias and their development in the unique genetic background of trisomy 21. A discussion is also provided for areas of future research and potential therapeutic development.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1096719212002673; http://dx.doi.org/10.1016/j.ymgme.2012.07.011; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84866159638&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/22867885; https://linkinghub.elsevier.com/retrieve/pii/S1096719212002673; http://www.mgmjournal.com/article/S1096-7192(12)00267-3/abstract
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know